In the 1970s, “Woodstock Weed” contained roughly 1–3% THC. Since then, potency of marijuana plant material has increased to an average potency of 18-23% today.

In 2017, THC concentrates had an average THC potency of 55.7%. Today, many retailers promote and profit from products containing up to 95–99% THC.

Americans 12 and older who reported using marijuana daily or almost daily increased from 6.2 million in 2009 to 13.8 million in 2019.

Daily users of high potency THC are five times more likely to develop a severe mental illness.

High potency and high frequency marijuana use are associated with the most severe impacts on mental health.
The concentration or potency of Tetrahydrocannabinol (THC), the psychoactive component of marijuana, has increased dramatically over the past few decades, both in plant material and in concentrates. Higher potency marijuana has been found to be more addictive, and the younger the user, the higher the likelihood of developing a Cannabis Use Disorder (CUD, or addiction). High potency marijuana exacerbates many of the consequences of marijuana use both short and long term, but translates to a big money maker for the pot industry. This is evidenced by their vociferous opposition to any potency cap even though ample evidence shows such a policy would likely improve health outcomes.

**Background: Dramatic Increase in Potency**

In the 1970s, “Woodstock Weed” contained roughly 1–3% THC. Since then, potency of marijuana plant material has steadily increased from 9.75% in 2009 to 14.88% in 2018 to an average potency of 18-23% today.

THC concentrates such as shatter, budder, and waxes—as well as gummies and edibles—are packed with more THC than joints ever were. One researcher said that “concentrates are as close to the cannabis plant as strawberries are to frosted strawberry Pop Tarts.”

Concentrates are often ingested by heating the concentrate until a vapor forms (dabbing), are consumed through food (edibles), are vaped, or are applied topically. In 2008, concentrates had an average THC potency of 6.7% but jumped to 55.7% in 2017. Today, many marijuana retailers promote and profit from products containing up to 95–99% THC.

**The Danger: Harms of High Potency Marijuana**

High potency and high frequency of marijuana use are associated with the most severe impacts on mental health.

**Short-term harms:**
- Overdoses
- Marijuana related Hospitalizations and ER visits
- Accidental child ingestion and a rise in marijuana-related poison control calls
- Cannabinoid hyperemesis syndrome (repetitive cycles of nausea and vomiting)

**Long-term harms:**
- THC addiction
- Psychosis
- Depression
- Anxiety
- Suicide
- Reshaping of brain matter
- Overdoses
- Marijuana related Hospitalizations and ER visits
- Accidental child ingestion and a rise in marijuana-related poison control calls
- Cannabinoid hyperemesis syndrome (repetitive cycles of nausea and vomiting)

- At least 56 scientific studies have confirmed the link between high potency marijuana and psychosis, including a 2020 study published in the Journal of American Medicine. This study found that high potency THC use was associated with “significant increases” in addiction and mental health disorders.

- A landmark 2019 study published in The Lancet concludes that the risk of psychosis triples when using products with 15% THC potency or higher, and daily users are five times more likely to develop a severe mental illness such as psychosis or schizophrenia.

- One study, published in Schizophrenia Research, found evidence to “suggest a psychotic risk with cannabis wax,” well beyond the already risky lower potency marijuana products.

Higher potency products are associated with the rise in daily and near daily use of marijuana. According to the Substance Abuse and Mental Health Services Administration, the number of Americans 12 and older who reported using marijuana daily or almost daily in the past 30 days increased from 6.2 million in 2009 to 13.8 million in 2019.
The Solution: Suggested Policies

There is no reputable evidence supporting the use of high THC concentrates for therapeutic purposes, and they are associated with the most harm. Cancer pain, outside of some very specific and rare forms of epilepsy, is generally the only medical condition where there exists more than just anecdotal evidence that some kind of marijuana use could be beneficial.23

A 2020 study found that 90% of marijuana products sold as “medical” marijuana featured THC levels in excess of 15% — which is about two to three times higher than the amount shown to provide neuropathic pain relief.24 The authors of this study recommended that “medical” marijuana regimes impose a THC potency limit of 10% or less to reduce the risk of short and long-term side effects.

Consider not allowing for the sale of concentrates altogether, aside from those in tinctures meant to be administered orally in droplets. The scant medical guidance available related to THC dosing recommends titrating up by 2.5mg or 5mg at a time and judging impact before increasing dose. All products sold should allow for this type of titration - i.e., not include high-potency flower (much less concentrates) that encourage very high THC dosing per administration session. Functionally, capping all product potency at 15%, or 5mg per unit of an edible (e.g., 5mg per gummy) is recommended.

Restrict edibles and concentrates as much as possible as they represent the most serious danger for public health. These products’ high potency, resemblance to non-laced consumer products (such as candy, lotions, etc.), and ease of use create serious, costly problems. They must be heavily regulated to prohibit their advertising, sales, and use.

Sample Legislative Language

Vermont has successfully adopted a potency cap on plant material (flower) and concentrates. The language adopted by the Vermont legislature that pertains to potency caps:

PROHIBITED PRODUCTS

(a) The following are prohibited products and may not be cultivated, produced or sold pursuant to a license issued under this chapter:

(1) cannabis flower with greater than 30 percent tetrahydrocannabinol;
(2) solid concentrate cannabis products with greater than 60 percent tetrahydrocannabinol;

Policy Success: Marijuana Potency Limit Success Story

In a 2018 study, researchers examined potency restrictions in the Netherlands.25 They found that marijuana potency doubled from just below 9% THC in 2000 to above 20% by 2004. This drastic increase was followed by a rise in the amount of people seeking treatment for marijuana issues. When the potency declined to 15% in 2015, treatment admissions for marijuana issues fell. Researchers estimated that for every 3% increase in THC potency, one person in 100,000 would seek first-time treatment for marijuana use disorder. These findings among others led the Netherlands to cap potency at 15%.26

Conclusion

As potency increases, negative harms increase. There is no reason the marijuana industry should be unchecked and left alone to create highly addicting and potent products and push them to consumers. The increasing demand for high potency marijuana products and the coinciding prevalence of marijuana use disorder are indicative of a future maelstrom with unknown consequences for public health, especially as the industry engages in a concerted effort to undermine scientifically proven risks of marijuana use. A potency cap is a rational way to reduce harms and potentially save lives.
Endnotes

16 Ibid.
17 Ibid.


